Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching
Policy Welcomed By Trade And Advocacy Groups
Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
